A Flawed Blockbuster and Its Challengers: clinic economics will decide psilocybin’s fate

Psilocybin’s ability to reach patients at scale depends less on antidepressant efficacy than on clinic economics and room-level throughput. The essay uses Spravato (intranasal esketamine) as a “blockbuster” case study, arguing it succeeded through structural operational advantages like buy-and-bill reimbursement, room scheduling, and monitoring workflows that let one treatment room cycle multiple patients in staggered observation windows. Psilocybin-assisted treatment (for example Compass Pathways’ COMP360-style model) is presented as operationally different: fewer sessions per year, longer single-session monitoring windows, and staffing requirements that may tether licensed clinicians and physicians to the session. That shift creates a potential mismatch between per-patient profit targets and per-room-day profit reality. The article further argues that payers may not need to believe psilocybin is clinically superior for it to disrupt Spravato’s revenue model. If an episodic psilocybin option is approved, payers can introduce or tighten duration limits, step-therapy requirements, and prior authorization pressure, especially given upcoming exclusivity and patent timelines.